129 related articles for article (PubMed ID: 38036098)
41. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
42. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway.
Wang Z; Ma Q; Liu Q; Yu H; Zhao L; Shen S; Yao J
Br J Cancer; 2008 Nov; 99(10):1695-703. PubMed ID: 19002187
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.
Ramos EA; Grochoski M; Braun-Prado K; Seniski GG; Cavalli IJ; Ribeiro EM; Camargo AA; Costa FF; Klassen G
PLoS One; 2011; 6(12):e29461. PubMed ID: 22220212
[TBL] [Abstract][Full Text] [Related]
44. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis.
Hernandez L; Magalhaes MA; Coniglio SJ; Condeelis JS; Segall JE
Breast Cancer Res; 2011; 13(6):R128. PubMed ID: 22152016
[TBL] [Abstract][Full Text] [Related]
45. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells.
Song ZY; Gao ZH; Chu JH; Han XZ; Qu XJ
Biomed Pharmacother; 2015 Apr; 71():46-52. PubMed ID: 25960214
[TBL] [Abstract][Full Text] [Related]
47. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
48. SOX17 inhibits proliferation and invasion of neuroblastoma through CXCL12/CXCR4 signaling axis.
Wang XH; Zhang SF; Wu HY; Gao J; Wang XH; Gao TH
Cell Signal; 2021 Nov; 87():110093. PubMed ID: 34302955
[TBL] [Abstract][Full Text] [Related]
49. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro.
Zhang C; Cui GH; Liu F; Wu QL; Chen Y
Acta Pharmacol Sin; 2006 Nov; 27(11):1438-46. PubMed ID: 17049119
[TBL] [Abstract][Full Text] [Related]
51. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
52. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
Del Prete GQ; Leslie GJ; Haggarty B; Jordan AP; Romano J; Hoxie JA
J Virol; 2010 Sep; 84(17):8777-89. PubMed ID: 20573813
[TBL] [Abstract][Full Text] [Related]
53. LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis.
Dong XZ; Zhao ZR; Hu Y; Lu YP; Liu P; Zhang L
Gastric Cancer; 2020 Mar; 23(2):260-272. PubMed ID: 31650323
[TBL] [Abstract][Full Text] [Related]
54. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
55. CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.
Chen N; Jiang X; Wang J; Wu T; Cheng B; Xia J
Tumour Biol; 2016 Jan; 37(1):567-75. PubMed ID: 26232325
[TBL] [Abstract][Full Text] [Related]
56. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
57. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
58. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
59. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.
Sleightholm RL; Neilsen BK; Li J; Steele MM; Singh RK; Hollingsworth MA; Oupicky D
Pharmacol Ther; 2017 Nov; 179():158-170. PubMed ID: 28549596
[TBL] [Abstract][Full Text] [Related]
60. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.
Singh AP; Arora S; Bhardwaj A; Srivastava SK; Kadakia MP; Wang B; Grizzle WE; Owen LB; Singh S
J Biol Chem; 2012 Nov; 287(46):39115-24. PubMed ID: 22995914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
